Veloxis Pharmaceuticals AS v. Zydus Cadila et al.

In a notable Hatch-Waxman case with significant market implications, specialty pharmaceutical company Veloxis Pharmaceuticals has sued Indian generic drug manufacturer Zydus for patent infringement. Filed in the U.S. District Court for the District of Delaware, the suit alleges that Zydus's proposed generic versions of ENVARSUS XR® will infringe on ten of Veloxis's patents. Veloxis, a U.S.-based subsidiary of Japan's Asahi Kasei, is an operating company focused on improving the lives of transplant patients; its key commercial product is ENVARSUS XR. The defendants, Zydus Cadila and its parent Zydus Lifesciences Ltd., form a major India-based pharmaceutical company that develops and manufactures a wide range of products, with a significant focus on generic drugs for the U.S. and other global markets. The lawsuit was triggered by Zydus's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA), seeking approval to market its own tacrolimus extended-release tablets before the expiration of Veloxis's patents.

The accused products are Zydus's 0.75 mg, 1 mg, and 4 mg extended-release tablets of tacrolimus, the active ingredient in Veloxis's ENVARSUS XR. ENVARSUS XR is a once-daily immunosuppressant drug used to prevent organ rejection in kidney transplant patients. It is a critical therapy for this patient population and a significant product for Veloxis. The ten patents asserted by Veloxis protect various aspects of the drug's formulation and use. The patents generally cover: stabilized pharmaceutical compositions of tacrolimus (U.S. Patent Nos. 9,549,918; 10,166,190; 11,110,081), extended-release oral dosage forms for once-daily treatment (U.S. Patent Nos. 8,685,998; 8,664,239; 11,123,331), methods of controlling tacrolimus blood concentration levels in patients (U.S. Patent No. 11,419,823), methods of achieving therapeutic effect with reduced side effects (U.S. Patent No. 10,864,199), and specific tacrolimus dosage forms and treatment methods (U.S. Patent Nos. 12,083,103; 12,403,095).

The case (1:26-cv-00467) is in its earliest stages, having been filed on April 23, 2026. The choice of the District of Delaware is significant, as it is the nation's leading venue for patent litigation, particularly for complex pharmaceutical disputes under the Hatch-Waxman Act. The court's judges are highly experienced in handling such cases, which involve intricate scientific and legal issues. This litigation is notable as it represents a classic battle between a brand-name drug innovator seeking to protect its market exclusivity and a generic manufacturer aiming to introduce a lower-cost alternative. The outcome will directly impact the availability and pricing of generic tacrolimus extended-release tablets in the United States, affecting patients, healthcare providers, and the financial performance of both Veloxis and Zydus. At this early stage, there are no known parallel Inter Partes Review (IPR) proceedings at the Patent Trial and Appeal Board, though such challenges are common in Hatch-Waxman disputes.

As of May 1, 2026, the patent infringement litigation Veloxis Pharmaceuticals AS v. Zydus Cadila et al. is in its nascent stages, with only the initial filings appearing on the court's docket. Key developments are detailed below.

Filing & Initial Pleadings

• 2026-04-23: Complaint Filed. Veloxis Pharmaceuticals, Inc. filed a patent infringement complaint against Zydus Pharmaceuticals (USA) Inc. and its parent company, Zydus Lifesciences Ltd., in the U.S. District Court for the District of Delaware (Case No. 1:26-cv-00467). The lawsuit was initiated under the Hatch-Waxman Act following Zydus's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). Veloxis alleges that Zydus's proposed generic extended-release tacrolimus tablets will infringe upon ten U.S. patents protecting Veloxis's branded drug, ENVARSUS XR®.
• 2026-04-23: Initial Procedural Filings. On the same day the complaint was filed, Veloxis also submitted several required documents:
  • A supplemental information form for cases involving an ANDA, which noted that Veloxis received notice of Zydus's ANDA on March 12, 2026, and that the statutory 30-month stay of FDA approval for the generic would expire on September 12, 2028. (D.I. 3)
  • A report to the U.S. Patent and Trademark Office identifying the ten patents-in-suit. (D.I. 4)
  • A corporate disclosure statement identifying Asahi Kasei Corp. as its parent company. (D.I. 5)
  • Summons were issued to the Zydus defendants. (D.I. 6)
• Current Status of Pleadings: As of May 1, 2026, the Zydus defendants have not yet filed an answer or any counterclaims. The deadline for a response to the complaint has not yet passed.

Pre-trial Motions, Claim Construction, and Discovery

Given that the case was filed only a week ago, there have been no substantive pre-trial motions, such as motions to dismiss or for summary judgment. The litigation has not progressed to key stages like claim construction (Markman hearings) or significant discovery events. A scheduling order governing these future milestones has not yet been entered by the court.

Trial, Verdict, and Final Disposition

The case is not close to trial, and no verdict, judgment, or settlement has been reached. The litigation remains open and pending its earliest procedural stages.

Parallel PTAB Proceedings

A search of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) records reveals no Inter Partes Review (IPR) or Post-Grant Review (PGR) proceedings filed by Zydus against the ten Veloxis patents asserted in this litigation. It is common for such challenges to be filed later in the litigation process.

Plaintiff's Counsel of Record

Plaintiff Veloxis Pharmaceuticals is represented by attorneys from Paul Hastings LLP, serving as lead counsel, and Potter Anderson & Corroon LLP, serving as local counsel in Delaware. The appearances were entered upon the filing of the complaint on April 23, 2026.

Based on an analysis of the initial complaint (D.I. 1) and associated filings, the following attorneys have appeared on behalf of the plaintiff:

Lead Counsel

Name	Role	Firm	Office	Notable Experience
Bruce M. Wexler	Lead Counsel	Paul Hastings LLP	New York	Co-chairs the firm's global IP practice and has extensive first-chair trial experience in high-stakes Hatch-Waxman patent litigation for major pharmaceutical clients.
Eric W. Dittmann	Lead Counsel	Paul Hastings LLP	New York	Global co-chair of the Intellectual Property practice, frequently leads major patent litigation in the pharmaceutical and biotechnology sectors, including cases for AbbVie and Allergan.
Scott F. Peachman	Of Counsel	Paul Hastings LLP	New York	Focuses on patent litigation in the pharmaceutical and chemistry fields, with significant experience representing innovator companies in Hatch-Waxman cases.
(Additional Paul Hastings attorneys may appear as the case progresses)

Local Counsel

Name	Role	Firm	Office	Notable Experience
David E. Moore	Local Counsel	Potter Anderson & Corroon LLP	Wilmington, DE	A partner in the firm's IP Group, he has served as Delaware counsel in numerous major patent litigations for a wide range of technology and pharmaceutical companies.
Bindu A. Palapura	Local Counsel	Potter Anderson & Corroon LLP	Wilmington, DE	A partner focusing on intellectual property and complex commercial litigation, frequently acting as Delaware counsel in significant patent disputes before the District Court.

This legal team composition is common in Delaware patent cases, combining a national firm with deep subject-matter expertise in Hatch-Waxman litigation (Paul Hastings) with a premier Delaware firm that provides essential familiarity with local court rules, practices, and judges (Potter Anderson & Corroon). The specific attorneys from both firms are seasoned patent litigators with substantial experience in pharmaceutical cases.

It should be noted that while these attorneys are listed on the initial filings, the full legal team may expand or change as the litigation proceeds. As of May 1, 2026, no in-house counsel for Veloxis has formally entered an appearance on the docket.

Defendant's Counsel of Record

As of May 1, 2026, defendants Zydus Cadila and Zydus Lifesciences Ltd. have not yet formally appeared in the case, and no counsel has been entered on the docket on their behalf.

The complaint was filed on April 23, 2026, and summons were issued the same day. The defendants' response, which would include the first appearance by their legal representatives, is not yet due under the Federal Rules of Civil Procedure.

Consequently, there are no attorneys of record for the defendants at this early stage of the litigation. This section will be updated as soon as defense counsel makes an appearance by filing an answer or other preliminary motion with the court.